The CHAMPION-AF trial's subgroup analysis, presented at EuroPCR 2026, evaluated stroke-prevention strategies in patients with atrial fibrillation (AF) by age. It compared the efficacy and safety of left atrial appendage closure (LAAC) and direct oral anticoagulant (DOAC) therapy. The study involved 1,915 patients under 75 years and 1,085 patients aged 75 and older. Results indicated that the primary efficacy endpoint, which included death from cardiovascular causes, stroke, or systemic embolism at 3 years, was similar for both LAAC and DOAC across age groups, with hazard ratios of 1.07 for younger patients and 1.34 for older patients. Notably, LAAC was associated with significantly lower rates of non-procedural bleeding compared to DOAC in both age groups. However, the incidence of ischemic strokes was higher in the LAAC group, although this difference was not significant when patients adhered to their assigned therapy. The findings suggest that age should not preclude the use of LAAC in suitable candidates and highlight the importance of shared decision-making between healthcare providers and patients regarding treatment options.